Fresenius Invests in BioIntellisense AI Platform
“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.
Read the full article » | Posted 09-12-2019
Related Articles
- Baxter ASN Presence, 2018 Posted 10-05-2026
- Fresenius Kidney Care Reports PD Breakthroughs Posted 10-05-2026
- NIH to Consolidate Websites Under Nine Hubs Posted 09-18-2026
- FDA Warns Fresenius About Leaking PD Solution Bags and Particulates Posted 09-18-2026